SelectQuote Q4 Call Prioritizes Cash Flow, Guides to >$60M FY27 OCF Despite Lower Revenue

What happened

In its Q4 FY26 earnings call, SelectQuote announced a strategic pivot toward cash flow and deleveraging, guiding for fiscal 2027 operating cash flow above $60 million while acknowledging expected lower revenue. This marks a significant upgrade from the prior FY26 operating cash flow guidance of $25–35 million and reflects management's focus on liquidity and balance sheet repair over Medicare Advantage policy growth. The revenue decline is consistent with ongoing softness in Senior segment submitted policies and carrier incentive pressure seen in recent quarters. The cash flow guidance appears to rely on continued working capital benefits from supplier payment terms, which the company previously cautioned may not be indicative of future trends, warranting scrutiny. The announcement comes as SLQT remains under an NYSE compliance clock, and the higher cash flow projection, if achieved, would materially improve debt service capacity given the ~10.2% term loan rate.

Implication

Investors should treat the >$60M FY27 operating cash flow guidance as a potentially transformative improvement, but its credibility hinges on whether it stems from repeatable operations or one-time supplier-term extensions. The lower revenue outlook suggests the business is shrinking in its core Medicare Advantage distribution, which could reduce long-term earnings power even as near-term liquidity improves. The stock's reaction will likely hinge on whether the market believes the cash flow can be sustained while the company remains below the NYSE $1.00 threshold; any failure to regain compliance could still trigger dilution or delisting. A successful deleveraging path would support the bull case, but the bear case remains intact if the cash flow proves to be timing-driven and revenue continues to contract. Overall, the news marginally improves the risk/reward but does not yet justify upgrading from WAIT without evidence that the cash flow is durable and the listing issue is resolved.

Thesis delta

Previously, the thesis hinged on FY26 OCF of $25–35M and NYSE compliance; the new FY27 guidance of >$60M OCF suggests cash conversion may be stronger than modeled, but it comes with explicit revenue decline. This shifts the debate from near-term solvency to the durability of cash flow amid a shrinking revenue base. The WAIT rating is maintained, but the bar for upgrading has been lowered slightly: if the company can demonstrate that the >$60M OCF is not reliant on one-time working capital and it regains NYSE compliance, the risk/reward improves materially.